under this system and its earlier prototype , eligible aids patients were able to receive pre-approval treatment with zidovudine and trimetrexate ( an experimental drug for the treatment of aids patients with pneumocystis carinii pneumonia who have experienced severe adverse reactions using standard approved therapies ) .
C0085176
trimetrexate
C1535939
pneumocystis carinii pneumonia